Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences, ProQinase Start Biomarker Project

NEW YORK (GenomeWeb News) – Proteome Sciences, ProQinase, and the NMI Natural and Medical Sciences Institute at the University of Tübingen have started a three-year project to establish new workflows for developing and evaluating inhibitors targeting tumor protein kinases, Proteome Sciences said today.

The aim of the BioTag project, which is funded by the German Federal Ministry of Research and NMI, is to develop biomarker tests that can support kinase target validation studies, establish proof of concept for candidate kinase inhibitors, and to monitor treatment response in pre-clinical and early clinical studies.

The project will develop new molecular strategies for target expression and biomarker profiling and develop biomarkers that will be used to translate early drug candidates into human clinical trials.

"The need for more objective measures of drug safety and efficacy during pre-clinical and clinical development is widely recognized and the adoption of biomarkers for such purposes is supported by the pharmaceutical industry and regulators," Proteome Sciences CEO Christopher Pearce said in a statement.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.